Loading clinical trials...
Loading clinical trials...
The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ironshore Pharmaceuticals and Development, Inc
NCT07541820 · Attention-Deficit Hyperactivity Disorder Symptoms, Attention-Deficit Hyperactivity Disorder
NCT05869253 · Attention-deficit Hyperactivity Disorder
NCT04416360 · Autism Spectrum Disorder, Attention-deficit Hyperactivity Disorder
NCT04638283 · Attention-Deficit Hyperactivity Disorder, Unspecified Type
NCT02699086 · Attention-Deficit Hyperactivity Disorder (ADHD)
Saskatoon Centre for Patient-Oriented Research, Royal University Hospital, Room 5681, C Wing
Saskatoon, Saskatchewan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions